Celldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024. In the quarter to June 2026, revenue fell 96.8%, EPS fell 10.6% and free cash flow fell 35.5%, each against the same quarter a year earlier.
Follow CLDX
Celldex Therapeutics, Inc. (CLDX) EV/Sales
As of 16 October 2026, Celldex Therapeutics, Inc. (CLDX) trades at a EV/Sales of 1,610×. Over the past ten years it has ranged from −10.7× (March 2020) to 3,131× (August 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 474× | 267.62% |
| FY2024 | 129× | (42.41%) |
| FY2023 | 224× | (69.56%) |
| FY2022 | 735× | 173.10% |
| FY2021 | 269× | 507.80% |
| FY2020 | 44.3× | — |
| FY2019 | −7.9× | — |
| FY2018 | −6.1× | — |
| FY2017 | 19.0× | (28.88%) |
| FY2016 | 26.8× | (88.13%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2,459× | 130.76% |
| Mar 2026 | 1,066× | 125.07% |
| Dec 2025 | 474× | 279.29% |
| Jun 2025 | 125× | 76.79% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 1.1× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| ADMA ADMA Biologics Inc compare | 4.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| VRDN Viridian Therapeutics, Inc. compare | 18.6× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 23.7× |
| SLS SELLAS Life Sciences Group, Inc. compare | 167× |
| CLDX Celldex Therapeutics, Inc. | 1,610× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)